叶酸联合阿托伐他汀对轻度认知功能障碍的疗效

目的探讨叶酸联合阿托伐他汀治疗患者轻度认知功能障碍的疗效。方法通过简易智能状态量表,将纳入的研究对象分为健康对照组(A组)和轻度认知障碍组(MCI组)。再根据是否给予药物干预治疗随机分为MCI未治疗组(B组)和MCI治疗组(C组)。三组均在治疗前后进行简易智能状态量表评定,并进行治疗前后及两组间对比。结果干预周期前后A组高同型半胱氨酸(Hcy)、胆固醇(TC)及简易精神状态量表(MMSE)值差异无统计学意义(P>0.05);B组MMSE值较之前有所下降,其差异有统计学意义(P<0.05),虽Hcy、TC水平有所上升,但差异无统计学意义(P>0.05);C组MMSE值较之前稍下降,但差异无统计学意义(P>0.05),Hcy、TC水平较之前显著降低(P<0.05)。结论 MCI患者其认知功能损害进展较健康对照组快,同时发现叶酸联合阿托伐他汀对MCI患者的认知功能的改善有一定作用。

Observations on the efficacy of folic acid and atorvastatin in treating mild cognitive impairment

Objective To assess the efficacy of folic acid and atorvastatin in treating mild cognitive impairment.Methods 77 people using MMSE scales were allocated to MCI groups,32 healthy people were as controls（control group）.MCI groups were randomly allocated to folic acid and atorvastatin group and control group.Evaluation was made using MMSE scales in every groups after treatment,A comparison was made between pretreatment and posttreatment and between the two groups.Results After treatment,there were no significant differences in blood Hcy,TC and MMSE scores in group A（P0.05）.In group B,MMSE scores was lower than before after treatment（P0.05）.Blood Hcy and TC level were higher than before after treatment,but there was no significant different（P0.05）.In group C,MMSE scores was lower than before,but there was no significant difference（P0.05）.Blood Hcy and TC level were significant lower than those before treatment（P0.05）.Conclusion Patients with mild cognitive impairment have a rapid decline of cognitive function.Folic acid combine with atorvastatin has an obvious advantage in improving their cognitive function.